Enanta Pharmaceuticals, Inc. (ENTA) vs X4 Pharmaceuticals, Inc. (XFOR)

Enanta Pharmaceuticals, Inc. and X4 Pharmaceuticals, Inc. are both Biotechnology companies. Enanta Pharmaceuticals, Inc. and X4 Pharmaceuticals, Inc. are of similar size ($304.4M and $293.6M). Enanta Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 0.70% against −50.1%. Enanta Pharmaceuticals, Inc. has the higher net margin (−96.9% vs −474.7%) and the higher return on invested capital (0.00% vs −178.2%). Across the 17 metrics below, Enanta Pharmaceuticals, Inc. leads on 11 and X4 Pharmaceuticals, Inc. on 6.

Valuation

Metric ENTA XFOR Biotechnology median
P/E n/m n/m 10.60
P/S 4.90 23.50 9.40
P/B 3.17 2.87 2.13
Price to free cash flow n/m 16.91 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 2.00 17.02 9.02
Earnings yield (21.91%) (21.26%) (32.88%)
Free cash flow yield (11.54%) 5.91% (23.13%)

Profitability

Metric ENTA XFOR Biotechnology median
Gross margin 100.00% 81.77% 68.51%
Operating margin (89.99%) (473.95%) 0.00%
Net margin (96.89%) (474.74%) 0.00%
Free cash flow margin (56.60%) (478.16%) 0.00%
Return on equity (70.12%) (80.32%) (51.96%)
Return on assets (21.15%) (40.73%) (46.06%)
Return on invested capital 0.00% (178.23%) 0.00%

Growth

Metric ENTA XFOR Biotechnology median
Revenue growth (TTM) 0.70% (50.08%) 6.76%
EPS growth (last fiscal year) 29.93% 67.23% 29.88%
Revenue growth, 5-year CAGR (11.81%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ENTA XFOR Biotechnology median
Debt to equity 0.00 0.55 0.00
Current ratio 3.76 13.22 4.97
Net debt to EBITDA 2.35 2.06 1.01

Dividend

Metric ENTA XFOR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ENTA XFOR Biotechnology median
Market cap 293.59m 304.38m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack